Microglia dysfunction in those who experienced early life adversity prompts an aberrant stress response during adulthood that may be linked to mental illness.
A molecular process caused by the TREM2 gene mutation in the brain's microglia increases the risk of Alzheimer's disease, a new study reports.
Niaspan, an FDA-approved drug, limits disease progression in lab models of Alzheimer's disease.
A new study in mice finds microglia help neurons grow synapses critical for cognitive function.
Infection with the SARS_CoV-2 virus causes dials down the action of olfactory receptors, resulting in smell loss associated with COVID-19.
Findings point to microglial TREM2 as a potential target for the treatment of ALS.
Microglia showed DNA methylation profiles that were distinct from other cells in the central nervous system.
Findings reveal a common Parkinson's disease genetic mutation drives mislocalization of iron in activated microglia.
Microglia, a key immune cell in the brain, appears to mediate the relationship between the gut microbiome and amyloid-beta deposits in male mouse models of Alzheimer's disease.
A drug currently being tested in cancer clinical trials appears to prevent dysfunction in an immune cell signaling pathway associated with Alzheimer's disease. Blocking the pathway could prevent Alzheimer's from developing and slow the progression of symptoms for those who already have the disease.
Physical activity appears to reduce microglial activation and improve cognition in the aging human brain, researchers report.
Researchers examine how neuroimmune interactions promote brain plasticity and shed new light on how neuroimmune activity may have implications for a range of disorders, including neurological changes experienced by COVID-19 survivors.
